NASDAQ:ANGO

AngioDynamics Stock Forecast, Price & News

$27.25
+0.28 (+1.04 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.71
$27.31
50-Day Range
$22.99
$28.41
52-Week Range
$8.68
$30.25
Volume440,333 shs
Average Volume285,190 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.82
30 days | 90 days | 365 days | Advanced Chart
Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.


AngioDynamics logo

About AngioDynamics

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

508th out of 1,309 stocks

Surgical & Medical Instruments Industry

49th out of 121 stocks

Analyst Opinion: 2.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

Is AngioDynamics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AngioDynamics stock.
View analyst ratings for AngioDynamics
or view top-rated stocks.

What stocks does MarketBeat like better than AngioDynamics?

Wall Street analysts have given AngioDynamics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AngioDynamics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release its next quarterly earnings announcement on Tuesday, October 5th 2021.
View our earnings forecast for AngioDynamics
.

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) issued its earnings results on Monday, March, 29th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.04. The medical instruments supplier earned $71.18 million during the quarter, compared to analyst estimates of $68.42 million. AngioDynamics had a positive trailing twelve-month return on equity of 0.41% and a negative net margin of 10.84%.
View AngioDynamics' earnings history
.

How has AngioDynamics' stock been impacted by COVID-19 (Coronavirus)?

AngioDynamics' stock was trading at $10.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ANGO stock has increased by 168.7% and is now trading at $27.25.
View which stocks have been most impacted by COVID-19
.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics issued an update on its FY 2022 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share guidance of $0.000-$0.050 for the period, compared to the Thomson Reuters consensus estimate of $0.070. The company issued revenue guidance of $305 million-$310 million, compared to the consensus revenue estimate of $297.90 million.

What price target have analysts set for ANGO?

2 brokers have issued 1 year price objectives for AngioDynamics' stock. Their forecasts range from $28.00 to $32.00. On average, they expect AngioDynamics' share price to reach $30.00 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts' price targets for AngioDynamics
or view top-rated stocks among Wall Street analysts.

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the following people:
  • Mr. James C. Clemmer, CEO, Pres & Director (Age 57, Pay $1.33M)
  • Mr. Stephen A. Trowbridge, Exec. VP & CFO (Age 47, Pay $629.55k)
  • Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 57, Pay $522.12k) (LinkedIn Profile)
  • Mr. Scott Centea, Sr. VP & GM of Vascular Interventions and Therapies & Peripheral Artery Disease (Age 43, Pay $558.54k)
  • Mr. Richard C. Rosenzweig, Sr. VP, Gen. Counsel & Company Sec. (Age 54)
  • Mr. Benjamin H. Davis, Sr. VP of Bus. Devel. (Age 57)
  • Ms. Marna I. Bronfen-Moore, Sr. VP of HR (Age 54)
  • Mr. Chad T. Campbell, Sr. VP & GM of Vascular Access Global Bus. Unit (Age 50)
  • Mr. Warren G. Nighan, Sr. VP of Quality & Regulatory Affairs (Age 52)
  • Ms. Kim L. Seabury, Sr. VP of Information Technology (Age 54)

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

27 employees have rated AngioDynamics CEO James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among AngioDynamics' employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AngioDynamics' key competitors?

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by many different retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (6.10%), Brinker Capital Investments LLC (0.11%), State of Alaska Department of Revenue (0.07%), Arizona State Retirement System (0.03%) and Advisor Group Holdings Inc. (0.00%). Company insiders that own AngioDynamics stock include Dave Helsel, James C Clemmer, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends for AngioDynamics
.

Which institutional investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Brinker Capital Investments LLC, Advisor Group Holdings Inc., and Arizona State Retirement System. Company insiders that have sold AngioDynamics company stock in the last year include Dave Helsel, and Wesley Johnson.
View insider buying and selling activity for AngioDynamics
or view top insider-selling stocks.

Which institutional investors are buying AngioDynamics stock?

ANGO stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer, and Stephen A Trowbridge.
View insider buying and selling activity for AngioDynamics
or or view top insider-buying stocks.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $27.25.

How much money does AngioDynamics make?

AngioDynamics has a market capitalization of $1.05 billion and generates $291.01 million in revenue each year. The medical instruments supplier earns $-31,550,000.00 in net income (profit) each year or $0.05 on an earnings per share basis.

How many employees does AngioDynamics have?

AngioDynamics employs 800 workers across the globe.

What is AngioDynamics' official website?

The official website for AngioDynamics is www.angiodynamics.com.

Where are AngioDynamics' headquarters?

AngioDynamics is headquartered at 14 PLAZA DRIVE, LATHAM NY, 12110.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]


This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.